-A Phase 2a study of BAER-101 in epilepsy is planned to initiate in 2024MIAMI, Aug. 01, 2023 (GLOBE NEWSWIRE) --…
David Long served on GBB Drink Lab’s Advisory Board, guiding the development and marketing of the world’s first rapid alcohol…
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTBURLINGAME, Calif., Aug. 01, 2023 (GLOBE…
Renowned Jamaican Psilocybin Cultivator and Supplier Expands Operations and Sets Eyes on U.S.RUNAWAY BAY, Jamaica, Aug. 01, 2023 (GLOBE NEWSWIRE)…
Sale Completes Awakn's Exit From Healthcare Services To Focus Solely on Biotechnology Research and DevelopmentToronto, Ontario--(Newsfile Corp. - August 1,…
VANCOUVER BC / ACCESSWIRE / August 1, 2023 / EMPOWER CLINICS INC. (CSE:EPW)(OTC PINK:EPWCF) ("Empower" or the "Company") announces today,…
This announcement contains inside informationStrategic Divestment of C4XD's Orexin-1 Receptor Antagonist Programme to Indivior for £15.95 MillionSale encompasses all rights…
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the…
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in…
– Revenue of $984.4 Million, GAAP Diluted EPS of ($0.16), and Non-GAAP Diluted EPS of $0.93 – – Total Company…